feedback

Course Director

George D. Demetri, MD
George D. Demetri, MD

Dana-Farber Cancer Institute
Ludwig Center at Harvard
Harvard Medical School
Boston, Massachusetts

Faculty

Alexander Drilon
Alexander Drilon, MD

Memorial Sloan Kettering Cancer Center
New York, New York

Brian Rubin
Brian Rubin, MD, PhD

Cleveland Clinic
Cleveland, Ohio

Accredited by

Medical Learning Institute, Inc.

View Activity Materials

Activity Description

In this new CME/MOC/CC activity, an expert panel discusses the diagnosis and management of NTRK gene fusion-positive cancers. Throughout this video, the panelists explore the diagnostic consensus for capturing gene fusions, and describe how pathologists and oncologists can collaborate to rapidly identify patients with TRK fusion cancers and recommend appropriate therapy options.

Target Audience

This activity has been designed to meet the educational needs of pathologists, oncologists, hematologist-oncologists, and other clinicians involved in treating cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Cite the current diagnostic and treatment consensus for adult and pediatric patients with TRK fusion cancers
  • Summarize the latest efficacy and safety data on the use of TRK inhibitors in patients with NTRK fusion-positive cancers
  • Employ effective diagnostic techniques for confirming the presence of NTRK fusions in solid tumors
  • Integrate TRK inhibitors into the management of NTRK fusion-positive tumors based on results of diagnostic testing, including for diseases such as lung, breast, and gastrointestinal cancers, among others

Providership, Credit, and Support


This CME/MOC/CC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Physician Continuing Medical Education

ACCMEThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC Credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Continuing Certification Statement

The activity titled “Modern Diagnostics and Targeted Therapy for TRK Fusion Cancers: Pathology-Oncologist Collaboration in the Era of Precision Medicine” has been registered to offer 1.0 Lifelong Learning (Accredited CME) credits in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit.

Participation information will be shared with ABPath through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Faculty Disclosures

Chair
George D. Demetri, MD
Senior Vice President for Experimental Therapeutics
Dana-Farber Cancer Institute
Co-Director, Ludwig Center at Harvard
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

George D. Demetri, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for EMD Serono, Inc.; GlaxoSmithKline; ICON plc; Medscape; MJ Hennessey/OncLive; Polaris Pharmaceuticals; sanofi-aventis U.S. LLC; and WCG/Arsenal Capital Partners. Consultant and/or Advisor with minor equity holding Bessor Pharma; Caprion/HistoGeneX; Caris Life Sciences; Champions Biotechnology; ErascaTM, Inc.; G1 Therapeutics, Inc.; and Relay Therapeutics.
Other Financial or Material Support from Novartis Pharmaceuticals Corporation royalty to Dana-Farber for use of patent of imatinib in GIST (Patents and royalties); Blueprint Medicines Corporation; Merrimack; and Translate Bio (Board of Directors member and Scientific Advisory Board Consultant with minor equity holding).

Faculty
Alexander Drilon, MD
Acting Chief of Early Drug Development
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbvie Inc.; AstraZeneca; BeiGene; BerGenBio ASA; Blueprint Medicines Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; Helsinn Healthcare SA; Hengrui Therapeutics, Inc.; Ignyta/ Genetech, Inc./ F. Hoffmann-La Roche Ltd.; Loxo Oncology/ Bayer/Eli Lilly and Company; MORE Health, Inc.; Pfizer Inc.; Remedica Ltd.; Takeda Pharmaceutical Company Limited/ARIAD Pharmaceuticals, Inc./Millenium Pharmaceuticals, Inc.; Turning Point Therapeutics, Inc; Tyra Biosciences, Inc.; and Verastem, Inc.
Grant/Research Support from Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; PharmaMar; Pfizer Inc.; Taiho Oncology, Inc.; and Teva Pharmaceuticals USA, Inc. (paid to institution).
Honoraria from Abbvie Inc.; AstraZeneca; BeiGene; BerGenBio ASA; Blueprint Medicines Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; Helsinn Healthcare SA; Hengrui Therapeutics, Inc.; Ignyta/Genetech, Inc./F. Hoffmann-La Roche Ltd.; Loxo Oncology/Bayer/Eli Lilly and Company; MORE Health, Inc.; Pfizer Inc.; Remedica Ltd.; Takeda Pharmaceutical Company Limited/ARIAD Pharmaceuticals, Inc./Millenium Pharmaceuticals, Inc.; Turning Point Therapeutics, Inc; Tyra Biosciences, Inc.; and Verastem, Inc.
Other Financial or Material Support from Boehringer Ingelheim GmbH. and Merus US, Inc.; travel expenses from Merck & Co., Inc. and Puma Biotechnology, Inc.

Brian Rubin, MD, PhD
Professor and Chairman of Pathology, Cleveland Clinic
Director, Soft Tissue Pathology
Cleveland, Ohio

Brian Rubin, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Avalon Healthcare Solutions; Caris Life Sciences; and Eli Lilly and Company.

Planning Committee Disclosures

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewers have nothing to disclose:

Jim Zhai, MD, FCAP
Janice Trainor-Tellier, MSN, RN

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain MOC/CC credit. There are no prerequisites and there is no fee to participate in this activity or to receive MOC/CC credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

About This CME/MOC/CC Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.